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Induction of Prostaglandin D2 through the p38 MAPK
Pathway Is Responsible for the Antipruritic Activity
of Sertaconazole Nitrate
Simarna Kaur1,2, Runa Sur1, Frank T. Liebel1 and Michael D. Southall1
Prostaglandin D2 (PGD2) is known to have antipruritic activity by suppressing histamine release. However,
agents that can topically induce PGD2 for itch relief are not well established. The antimycotic sertaconazole
nitrate (STZ) has been shown to exhibit anti-itch properties; however, the mechanism for this activity has not
been elucidated. STZ mitigated degranulation of RBL-2H3 (rat basophilic leukemia) mast cells induced by
compound 48/80, a pruritogenic agent known to promote the release of histamine, and augmented PGD2
production in mast cells and macrophages. Addition of exogenous PGD2 abrogated compound 48/80-induced
degranulation by acting through the prostanoid D receptor 1 (DP1). STZ induced p38 mitogen-activated protein
kinase (MAPK) phosphorylation in mast cells and a pharmacological inhibitor of p38 MAPK, SB203580, resulted
in the attenuation of PGD2 levels. Finally, in a murine model of pruritus, the scratching behavior induced by
compound 48/80 was mitigated by topical application of STZ. This effect was reversed by the addition of the
cyclooxygenase inhibitor, ibuprofen, or a DP1 receptor antagonist (MK0524). Collectively, these results suggest
that STZ mediates its anti-itch effects by boosting the antipruritic agent, PGD2, by the activation of the p38-
MAPK pathway. This is the first report to demonstrate a promising approach to topically induce PGD2 for
improving pruritus.
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INTRODUCTION
Pruritus (itching) has been characterized as an unpleasant
sensation that elicits the desire to scratch (Rothman, 1941)
and can range in severity from acute to intractable. Pruritus
can lead to a vicious itch–scratch cycle resulting in disrupted
skin integrity and subsequent decreased barrier resistance to
infections (Yosipovitch, 2004; Yosipovitch and Papoiu,
2008). Itching has also been characterized as a major
symptom in several forms of dermatitis, including atopic
dermatitis (AD) (Williams et al., 1994). The act of scratching
leads to the release of inflammatory mediators that potentially
induce or aggravate the skin condition resulting in the
itch–scratch cycle (Sta¨nder et al., 2006, 2008). Dermal mast
cells act very closely with nerve fibers and contain
substances, such as histamine, which act as both direct and
indirect mediators of pruritus (Sta¨nder et al., 2008).
Several lines of evidence suggest that Prostaglandin D2
(PGD2), which is produced primarily by skin mast cells
(Lewis et al., 1982; Peters et al., 1984) and macrophages (Cao
et al., 2008) functions as a natural antipruritic agent (Arai
et al., 2004; Honma et al., 2005) by suppressing histamine
release from mast cells (Chan et al., 2000; Hashimoto et al.,
2005). PGD2 is a metabolite of arachidonic acid released
from membrane phospholipids membrane by phospholipase
A2, and produced by the action of cyclooxygenase (COX) and
prostaglandin D synthase (PGDS) enzymes (Larsen and
Henson, 1983). In the biosynthesis pathway, there are two
PGD2 synthases that isomerize PGH2 to PGD2: lipocalin-type
PGDS and hematopoietic PGDS (Kanaoka and Urade, 2003).
Although the lipocalin-type PGDS is found in the central
nervous system and male genital organs, the hematopoietic
PGDS is expressed and localized in immune and inflamma-
tory cells, such as antigen-presenting cells, mast cells, and
megakaryocytes (Urade and Hayaishi, 2000; Kanaoka and
Urade, 2003). Two receptors for PGD2 have been characte-
rized: prostanoid D receptor (DP)1 and DP2. Both these
Prostanoid D receptors belong to the G protein-coupled
receptor family. DP1 is the most studied PGD2 receptor and
its activation leads to Gs-mediated elevation in cAMP. The
DP2 or chemoattractant receptor-homologous molecule
expressed on T helper2 cells receptor is homologous to the
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chemoattractant receptor that is expressed on T-helper type 2
cells. The two receptors vary in their cellular expression: the
DP1 receptor is the subtype found in mast cells, whereas the
DP2 receptor is expressed in T-helper type 2 cells, basophils,
etc. (Park and Christman, 2006).
PGD2 is involved in the regulation of several physiological
and pathophysiological processes, such as sleep induction,
vasodilatation, recruitment of inflammatory cells, allergic
asthma, platelet aggregation, etc. (Kanaoka and Urade,
2003). There is also emerging evidence pointing toward the
potential role of this prostanoid in skin and wound repair
(Ka¨mpfer et al., 2003, 2005). Recent studies have provided
new insights into the role of PGD2 in the suppression of
scratching behavior in mice (Arai et al., 2004; Honma et al.,
2005; Futaki et al., 2007). Using NC/Nga mice as a model for
AD, it was observed that topical application of PGD2 resulted
in a remarkable inhibition of itching in mice, even at low
doses (Arai et al., 2004). In the same strain of mice, cutaneous
barrier disruption caused by mechanical scratching led to
elevated levels of prostaglandins, with marked increases
observed for PGD2 and PGE2 levels, suggesting a physiolo-
gical role of these prostanoids in the repair of the skin
damaged by scratching (Futaki et al., 2007). Scratching
caused by ovalbumin injected into ovalbumin-sensitized
mice was also suppressed by PGD2, suggesting that this
prostanoid decreased IgE-mediated scratching by inhibiting
the corresponding histamine release from activated mast cells
(Hashimoto et al., 2005).
The broad-spectrum antifungal agent sertaconazole nitrate
(STZ) (Pfaller and Sutton, 2006) has been shown to exhibit
anti-inflammatory and anti-itch activities (Agut et al., 1996;
Liebel et al., 2006). Using a murine model of Substance
P-induced itch, we previously demonstrated that STZ inhibits
the scratching response in mice The anti-inflammatory
activity of STZ was recently shown to be mediated through
the p38–COX-2–PGE2 mechanism, in which STZ induced
PGE2 production through the p38-mitogen-activated protein
kinase (MAPK) pathway (Sur et al., 2008a). However,
signaling mechanism(s) that govern the antipruritic activity
of STZ are not fully understood. In this study, we explore the
pathway by which STZ mediates its anti-itch activity. This is
the first study to show that a topical antimycotic agent, STZ
mediates its antipruritic activity by enhancing PGD2 levels in
mast cells and macrophages by induction of the p38-MAPK
pathway. Elevated PGD2 levels attenuate mast cell degranu-
lation, leading to anti-itch response. The antipruritic activity
of STZ may contribute significantly to its application in fungal
infections in which itch is a predominant symptom. The use
of this particular antimycotic agent could provide additional
benefits to patients with fungal infections toward relieving
multiple conditions, including inflammation and itch.
RESULTS
STZ reverses compound 48/80-induced degranulation of mast
cells and stimulates PGD2 levels through the p38-MAPK
pathway
Degranulation of mast cells leading to the release of
histamine, the enzymes tryptase and b-hexosaminidase, and
other mediators, has been confirmed as one of the most
important factors inducing pruritus and an important target
for curing chronic itch (Yamashita et al., 2007). Thus,
compounds that suppress degranulation of mast cells can
potentially be of high value in anti-itch therapy. Therefore,
we first looked at compound 48/80-induced degranulation in
rat basophilic leukemia (RBL-2H3) mast cells to assess
antipruritic activity. The secretagogue, compound 48/80
was added alone or in conjunction with the indicated
concentrations of STZ, and a time course study was
performed to look at time points ranging from 15minutes to
6 hours (data for 1–6 hours time points not shown). Treatment
with compound 48/80 for 30minutes led to the release of
B21% of the granule marker b-hexosaminidase from mast
cells. STZ was found to significantly reverse the degranula-
tory effect of compound 48/80 in RBL-2H3 cells as early as
15 (Figure 1a) and 30minutes (Figure 1b) after treatment with
the secretagogue by approximately 30–40% overall. The
antimycotic did not exert a significant effect on mast cell
degranulation when evaluated in the absence of compound
48/80 induction (data not shown). To further dissect the
mechanism, PGD2 levels were analyzed from the same
supernatants that were initially tested for b-hexosaminidase
release by using competitive PGD2 ELISA. STZ enhanced the
levels of PGD2 (1,400–1,800 pgml
1) produced by com-
pound 48/80 starting at the 30-minute time point (Figure 1c),
and this increase was more pronounced at higher time points.
In the absence of compound 48/80 induction, STZ alone led
to B40% increase in PGD2 levels (data not shown). A
pharmacological inhibitor of p38 MAPK, SB203580, was also
tested to evaluate the pathway by which STZ mediates its
anti-itch effects. Pretreatment with SB203580 suppressed the
above-mentioned effects of STZ on mast cell degranulation
and PGD2 production (Figures 1a–c). The inhibitor alone led
to 11.1±2.3% increase in mast cell degranulation and no
change in PGD2 release when compared with the corre-
sponding vehicle control (in the absence of any inducing
agent) after 30minutes of treatment (data not shown). As mast
cell degranulation is a good measure for pruritic activity,
suppression of b-hexosaminidase release in combination with
the induction of PGD2 by STZ provides strong evidence that
this antifungal agent mediates its antipruritic activity by
augmenting PGD2 levels.
STZ enhances PGD2 levels in LPS-stimulated macrophages and
compound 48/80-stimulated mast cells after 24 hours of
treatment through the p38-MAPK pathway
PGD2 is primarily expressed in skin mast cells and macro-
phages (Lewis et al., 1982; Peters et al., 1984; Cao et al.,
2008); therefore, we further evaluated the levels of PGD2 in
both these cell types after stimulation with compound 48/80
or lipopolysaccharide (LPS) in conjunction with STZ. To
verify whether the previously observed increase in PGD2
production was a transient or long-term effect, murine
macrophages RAW-264.7 and RBL-2H3 mast cells were
treated with LPS (Figure 2a) or compound 48/80 (Figure 2b)
alone or in combination with the indicated concentrations of
STZ for 24 hours. GD2 levels were measured 24 hours after
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treatment by ELISA. Data confirmed that STZ enhanced LPS-
or compound 48/80-induced PGD2 levels in macrophages
and mast cells, respectively, at 24 hours. This effect was
reversed by the addition of the p38 inhibitor, SB203580,
emphasizing that STZ exerts its effects through the p38-MAPK
pathway (Figures 2a and b). The inhibitor alone led to a
4.4±3.9% decline in mast cell degranulation when com-
pared with the corresponding vehicle control (in the absence
of any inducing agent) after 24 hours of treatment (data not
shown). These observations are significant in confirming the
role of STZ in enhancing PGD2 levels in both the primary cell
types that express PGD2 synthase.
Exogenous PGD2 reverses the degranulatory effects of
compound 48/80 in mast cells. A selective DP1 receptor
antagonist, MK0524 blocks the effects of PGD2 and STZ on mast
cell degranulation
The degranulation and PGD2 ELISA results discussed
previously suggest that STZ suppresses degranulation of mast
cells by enhancing PGD2 levels. To confirm the role of PGD2
as an antipruritic agent, we investigated whether addition of
exogenous PGD2 would have a direct effect on mitigating
compound 48/80-induced degranulation of RBL-2H3 mast
cells. Cultured cells were pretreated with mutiple doses of
exogenous PGD2 for 30minutes, followed by treatment with
compound 48/80 for 30minutes. At that point, supernatants
(culture media) and pellets were separated and analyzed for
the degranulation marker b-hexosaminidase. Exogenously
added PGD2 directly suppressed degranulation in mast cells
caused by compound 48/80 in a dose-dependent manner by
450%, thus underlining the role of this prostanoid as a
natural antipruritic agent (Figure 3a). Mast cells have been
shown to express the DP1 receptor for PGD2 (Park and
Christman, 2006). To demonstrate that PGD2 acts through
this receptor in curtailing mast cell degranulation, we used a
selective DP1 receptor antagonist, MK0524, to block those
effects. Cultured RBL-2H3 cells were pretreated with two
doses (20 and 50 mM) of MK0524 for 1 hour, followed by
treatment with exogenous PGD2 and/or compound 48/80 for
30minutes each. Samples were analyzed for the degranula-
tion marker b-hexosaminidase. Although the lower dose of
the receptor antagonist (20 mM) did not have a significant
effect on mast cell degranulation caused by compound 48/80,
the higher dose (50 mM) significantly enhanced degranulation.
Pretreatment of cells with MK0524 (50mM), followed by
addition of exogenous PGD2 resulted in abrogation of
the effects of PGD2 on decreasing degranulation (Figure 3b).
The DP1 receptor antagonist was also successful in reversing
the activity of STZ on decreasing compound 48/80-induced
mast cell degranulation (Figure 3c), thus confirming that
STZ exerts its antipruritic effects through PGD2. In control
experiments, treatment of mast cells with MK0524 in the
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Figure 1. Sertaconazole nitrate reverses compound 48/80-induced degranulation of mast cells and stimulates PGD2 levels through the p38-MAPK pathway.
RBL-2H3 mast cells were pretreated with the p38 MAPK inhibitor, SB203580 (10 mM), for (a, c) 30 or (b) 45minutes, followed by another pretreatment with
the indicated concentrations of STZ for 30minutes. After the pretreatments, compound 48/80 (30 mgml1) was added to the cells for (a) 15 or (b) 30minutes. The
supernatants and pellets were assayed for the release of the granule marker b-hexosaminidase as an indicator of mast cell degranulation. (c) Supernatants
collected after 30minutes of compound 48/80 treatment were also used to assess PGD2 levels by ELISA. A one-way analysis of variance with Newman–Keuls
post hoc test was used to determine significance, *Po0.05 vs. uninduced control; **Po0.05 vs. 48/80; ***Po0.05 vs. 48/80þ corresponding dose of STZ.
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absence of any inducing agent, for 1 hour, led to 7.3±5.3%
decline in b-hexosaminidase release when compared with
the corresponding vehicle. Similar results were obtained
when the cells were treated with exogenous PGD2 without
compound 48/80 induction; a decline of 7.9±5.1% in mast
cells degranulation was observed by using 100 mM dose of
PGD2 (data not shown). Overall, these results provide further
evidence that PGD2 acts through the DP1 receptor in its
scope as a physiological antipruritic agent, and are consistent
with previously published reports on the anti-itch activity of
PGD2 in murine models of AD and mast cells (Chan et al.,
2000; Arai et al., 2004; Hashimoto et al., 2005; Honma et al.,
2005; Futaki et al., 2007).
STZ leads to the activation of p38 MAPK in mast cells
We have previously shown that STZ induces the p38-MAPK
pathway in primary human keratinocytes, leading to an anti-
inflammatory response by the production of PGE2 (Sur et al.,
2008a). Results discussed so far confirm the role of p38
MAPK in lowering degranulation and augmenting PGD2
levels by STZ (Figures 1 and 2). To corroborate these results,
we sought to determine whether this antifungal agent leads to
the direct activation of the p38-MAPK pathway in mast cells.
RBL-2H3 cells were treated with STZ (1 mgml1) for a time-
course study ranging from 15 to 60minutes. Western blotting
with the phospho-p38 antibody confirmed that STZ led to the
activation of p38 MAPK in mast cells, with more than two-
fold increase in the phosphorylation of the p38 protein at the
15-minute time point (Figure 4). The same blot was then
stripped and reprobed with total p38 MAPK and a/b-tubulin
antibodies to show equal protein loading.
Topical treatment with STZ inhibits scratching in a murine
model of pruritus through the PGD2 pathway
To validate our in vitro results, we used ICR mice, which are
a good model for evaluating itch mediators and mechanisms
(Inagaki et al., 2001). Control, shaved mice scratched an
average of 8.0±7.9 times, whereas those injected with the
vehicle (saline) scratched 9.0±9.6 times in a 30-minute time
period. These mice were pretreated with a topical application
of STZ for 30minutes. Compound 48/80, prepared in sterile
physiological saline, was injected into the interscapular part
of the back of the mice, and the number of scratches was
counted. STZ significantly inhibited the number of scratches
elicited by compound 48/80 treatment in mice by
42.5±7.2% as shown in Figure 5a. Pretreatment with EtoH
vehicle alone for 30minutes before compound 48/80
treatment had no significant effect on decreasing scratching,
the average scratches from 80.7±5.4 to 76.9±4.3 times in a
30-minute time period. To further assess the mechanism of
action, a nonselective COX inhibitor, ibuprofen, or a
selective DP1 receptor antagonist, MK0524, was also
topically applied for 30minutes pretreatment, followed by
sertaconazole or compound 48/80 treatments. The inhibitory
effect of STZ on scratching was significantly reversed by the
application of ibuprofen or the PGD2 receptor antagonist,
thus confirming that the anti-itch activity of STZ is mediated
through PGD2 (Figure 5b). It is also noteworthy that blocking
the DP1 receptor by using MK0524 (in the absence of STZ
treatment) augmented the scratching behavior in mice
elicited by compound 48/80 (Figure 5b), thus confirming
that PGD2 acts as a physiological antipruritic agent.
DISCUSSION
We have previously shown that STZ, an imidazole-type
antifungal agent elicits anti-itch response in a Substance
P-induced murine model of pruritus (Liebel et al., 2006). The
anti-inflammatory properties of STZ were recently attributed
to an increase in PGE2 production through the p38-MAPK
pathway (Sur et al., 2008a). However, signaling mecha-
nism(s) governing the anti-itch effects of this antimycotic are
still poorly understood. In this study, we sought to elucidate
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Figure 2. Sertaconazole nitrate enhances PGD2 levels after 24-hour
treatments in LPS-stimulated macrophages and compound 48/80-stimulated
mast cells through the p38-MAPK pathway. (a) Murine macrophages RAW-
264.7 and (b) RBL-2H3 mast cells were treated with (panel a) LPS
(100 ngml1) or (panel b) compound 48/80 (30 mgml1) alone or in
combination with the indicated concentrations of sertaconazole nitrate (STZ)
after 30-minute pretreatment with the p38 MAPK inhibitor, SB203580 (10 mM),
and PGD2 levels were measured 24hours later by ELISA. A one-way analysis
of variance with Newman–Keuls post hoc test was used to determine
significance. *Po0.01 vs. (panel a) LPS or (panel b) compound 48/80;
**Po0.01 vs. (panel a) LPSþ corresponding dose of STZ or (panel b)
compound 48/80þ STZ. LPS, lipopolysaccharide; MAPK, mitogen-activated
protein kinase; PGD2, Prostaglandin D2; RBL-2H3, rat basophilic leukemia.
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the mechanism of action by which STZ inhibits the itch
response induced by the pruritogen, compound 48/80.
The 2H3 sublines of RBL-2H3 cells are analogs of mast
cells that degranulate and have been used extensively to
study the biochemical pathways for secretion in mast cells
(Barsumian et al., 1981). Upon activation, these cells release
histamine and b-hexosaminidase, which are stored in the
secretory granules and are used as markers for mast cell
degranulation (Schwartz et al., 1981; Yamada et al., 2007).
To mimic a pruritogenic response, we used compound 48/80,
a mixture of polymers derived from N-methyl-p-methoxy-
phenylethylamine, which belongs to a family of polybasic
mast cell secretagogues (Chahdi et al., 2000), and has been
shown to induce histamine release from mast cells by
multiple mechanisms (Rothschild, 1970; Koibuchi et al.,
1985).
Degranulation of mast cells is one of the most important
factors in the induction of pruritus and an important target for
chronic itch (Yamashita et al., 2007). Therefore, we first
elicited a degranulatory response in mast cells by the action
of compound 48/80, and conducted a time-course study in
which STZ was added to the cells in conjunction with this
polybasic secretagogue. We observed that treatment with
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Figure 3. Exogenous PGD2 reverses the degranulatory effects of compound 48/80 in mast cells in a dose-dependent manner. Selective DP1 receptor
antagonist, MK0524, augments degranulation by blocking the effects of exogenous PGD2 and sertaconazole nitrate. (a) Cultured RBL-2H3 mast cells were
pretreated with the indicated doses of exogenous PGD2 (10 nM–100mM) for 1 hour, followed by treatment with compound 48/80 (30mgml
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degranulation. A one-way analysis of variance with Newman–Keuls post hoc test was used to determine significance. *Po0.01 vs. uninduced control; **Po0.01
vs. 48/80. (b) Mast cells were pretreated with two doses of the DP1 receptor antagonist MK0524 (50mM) alone for 1 hour, and/or followed by cotreatment with
exogenous PGD2 (10 mM) for 30minutes before the addition of compound 48/80 for 30minutes as indicated. A one-way analysis of variance with
Newman–Keuls post hoc test was used to determine significance. *Po0.05 vs. 48/80; **Po0.05 vs. 48/80þMK0524. (c) RBL-2H3 cells were pretreated with
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prostanoid D receptor 1; PGD2, Prostaglandin D2; RBL-2H3, rat basophilic leukemia; STZ, sertaconazole nitrate.
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Figure 4. Sertaconazole nitrate leads to the activation of p38 MAPK in mast
cells. RBL-2H3 mast cells were treated with STZ (0.5 or 1 mgml1) for the
indicated time periods, followed by protein analysis. Whole-cell extracts were
western blotted and probed with respective antibodies as indicated. Results
show that treatment with STZ resulted in the activation of p38 MAPK, without
affecting the levels of total p38. MAPK, mitogen-activated protein kinase;
RBL-2H3, rat basophilic leukemia; STZ, sertaconazole nitrate.
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compound 48/80 led to the degranulation of mast cells under
the conditions we tested, whereas preincubation with STZ
reversed those effects at 15 and 30minutes exposure to the
secretagogue (Figures 1a and b). Similar results were also
recorded for longer time points evaluated (data not shown).
Mitigation of mast cell degranulation by STZ is a good
indicator of its antipruritic efficacy, falling along the lines of
earlier studies reported by us (Liebel et al., 2006).
There have been some previous reports in literature that
RBL-2H3 mast cells do not respond to nonimmunological
stimuli such as compound 48/80 without being cocultured
with fibroblasts (Swieter et al., 1993) or sensitized with the
kinase inhibitor, quercetin (Senyshyn et al., 1998; Chahdi
et al., 2000). We tested the response of RBL-2H3 cells to
compound 48/80 in the absence and presence of prolonged
exposure to quercetin and analyzed degranulation levels. In
contrast, we recorded no significant difference in the levels of
b-hexosaminidase release in RBL-2H3 cells pretreated with
quercetin when compared with untreated cells under the
conditions we tested (data not shown). It is possible that
media conditions and high cell-passage number might have a
role in the response of these cells to compound 48/80. We
observed a trend toward lower degranulation in these cells at
high passages. In addition, the end point being measured in
this case (b-hexosaminidase release) is different from those
looked at in some of the previous reports. As a result, studies
mentioned in this paper were conducted in RBL-2H3 cells in
the absence of any pretreatment with the kinase inhibitor,
quercetin.
Several reports in literature suggest that PGD2 might serve
to attenuate pruritogenic (itch) responses in animal models of
AD and mast cells (Chan et al., 2000; Arai et al., 2004;
Hashimoto et al., 2005; Honma et al., 2005; Futaki et al.,
2007). As this prostanoid is primarily expressed in mast cells
and macrophages (Lewis et al., 1982; Peters et al., 1984; Cao
et al., 2008), we decided to investigate whether STZ alters
PGD2 levels in RBL-2H3 mast cells and RAW-264.7
macrophages. Corresponding to the time points evaluated
in the mast cell degranulation assay, PGD2 levels were also
measured using competitive ELISA. STZ boosted PGD2
production in mast cells starting at 30minutes treatment
(Figure 1c). In addition to these short-term effects, we also
observed that STZ boosted PGD2 produced by mast cells in
response to compound 48/80 after treatment for 24 hours
(Figure 2a). Similar results were obtained in the macrophages,
in which induction of PGD2 production by LPS was further
stimulated by STZ (Figure 2b) at the 24-hour time point. In
addition, we also observed analogous results with STZ on IgE-
mediated induction of PGD2 in RBL-2H3 mast cells,
confirming that these effects are not restricted only to 48/
80-induced PGD2 production (data not shown).
To further elucidate the endogenous antipruritic effects of
PGD2 and to confirm whether this postanoid has a direct
influence on mast cell degranulation, we exogenously added
PGD2 to RBL-2H3 cells and monitored compound 48/80-
induced degranulation. Pretreatment of mast cells with PGD2
before compound 48/80 directly mitigated degranulation in a
dose-dependent manner (Figure 3a). These effects were
reversed in the presence of a selective DP1 receptor
antagonist, MK0524 (Figure 3b). It is also notable that
blocking the PGD2 receptor by using MK0524 (at 50 mM
dose) significantly increased mast cell degranulation caused
by compound 48/80 (Figure 3b), and inverted the effects of
STZ on decreasing degranulation (Figure 3c). Our results
corroborate previously published reports (Chan et al., 2000;
Arai et al., 2004; Hashimoto et al., 2005; Honma et al., 2005;
Futaki et al., 2007) on the anti-itch effects of PGD2. It has also
been previously reported that agents that induce and sustain
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Figure 5. Topical treatment with sertaconazole nitrate inhibits scratching
behavior in a murine model of pruritus through the PGD2 pathway. ICR mice
were pretreated for 30minutes with topical application of 1% STZ. Compound
48/80 (50mg/50ml w/v) was injected into an area on the back of the mice,
and the number of scratches was counted in a 30-minute period. (a) Compound
48/80 drastically enhanced scratching in mice (n¼ 14 mice), which was
significantly inhibited by treatment with 1% STZ ((n¼ 10 mice) (panel a). This
reduction in itch was reversed by cotreatment of STZ with topical ibuprofen
((1% in ethanol) (n¼8 mice)). A one-way analysis of variance with
Newman–Keuls post hoc test was used to determine significance.*Po0.05 vs.
no 48/80 treatment, **Po0.05 vs. 48/80, ***Po0.05 vs. 48/80þ STZ.
(b) To confirm the mechanism of action, 50ml volume of a selective DP1
receptor antagonist, MK0524 (0.1% in ethanol), was topically applied for
30minutes pretreatment (n¼ 8–11 mice), followed by STZ and/or compound
48/80 treatments (panel b). A one-way analysis of variance with
Newman–Keuls post hoc test was used to determine significance. *Po0.05 vs.
no 48/80 treatment, **Po0.05 vs. 48/80, ***Po0.05 vs. 48/80þ STZ. PGD2,
Prostaglandin D2; STZ, sertaconazole nitrate.
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intracellular cAMP levels attenuate the release of mediators
from mast cells (Peachell et al., 1988; Weston and Peachell,
1998). PGD2 and BW245C (DP receptor-specific agonist)
have also been shown to enhance cAMP levels in CHO cells
transfected with the DP1 receptor (Hirata et al., 1994), and in
rat peritoneal mast cells (Lau and Chan, 2001). Taken together,
our results showing the inhibition of mast cell degranulation by
PGD2 through the DP1 receptor may potentially be attributed
to the activation of adenyl cyclase by the Gs protein, leading to
the increased production of cAMP.
The p38 MAPK is known to have a role in proinflamma-
tory cytokine production in response to various external
stimuli (Saklatvala, 2004; Borders et al., 2008). We have also
shown that activation of this kinase by STZ in keratinocytes
can lead to nonclassical anti-inflammatory effects by the
production of PGE2 (Sur et al., 2008a). To further dissect the
mechanism for the antipruritic effects of STZ, we used a
pharmacological inhibitor of p38 MAPK, SB203580. Pre-
treatment of RBL-2H3 mast cells with SB203580 reversed the
effects of STZ on attenuation of mast cell degranulation
(Figures 1a and b) and PGD2 production in mast cells and
macrophages, both (Figures 1a–c and 2a and b) highlighting
the role of this signaling pathway in mediating the anti-itch
effects of STZ. We also confirmed that STZ induces
phosphorylation of the p38 MAPK protein in mast cells by
western blotting (Figure 4). A time-course study was
performed in which RBL-2H3 cells were treated with the
antimycotic, and cell lysates were analyzed for phospho-p38
MAPK, followed by total p38 MAPK and a/b-tubulin to verify
equal protein loading. STZ led to the activation of p38 MAPK
within 15minutes, and this induction remained unchanged
until at least 60minutes. These results corroborate our initial
observations signifying that the p38-MAPK pathway is
involved in the antipruritic effects of STZ by the production
of PGD2. Other antifungal agents, such as butoconazole,
fluconazole, terconazole, tioconazole, or ketoconazole,
failed to stimulate the p38-MAPK pathway (data not shown),
suggesting that the above-described activity is independent of
the azole structure, and is specific to STZ.
Owing to the fact that STZ resulted in abrogation of mast
cell degranulation in the 15-minute time period, and
escalated PGD2 levels in 30minutes, we hypothesized that
under these conditions, the synthesis of PGD2 might involve
COX-1-mediated liberation of arachidonic acid. Using
specific COX-1 and COX-2 inhibitors, it has been previously
shown that abrogation of COX-1 is associated with increased
scratching behavior in mice, which is improved by the
topical application of PGD2 (Sugimoto et al., 2006a). In a
separate study, mechanical scratching caused by a stainless-
steel wire brush led to elevated PGD2 levels in a 10-minute
time period, signifying the involvement of the COX-1
isozyme, especially as COX-2 was shown to be induced
after 3 hours (Sugimoto et al., 2006b). In the same report, it
was also shown that levels of PGD2 and some other
prostanoids were markedly lower in the scratched skin of
COX-1-deficient mice. However, only PGD2 levels were
suppressed in the normal skin of COX-1-deficient mice,
collectively suggesting that cutaneous PGD2 could be
primarily produced by the action of the COX-1 enzyme
(Sugimoto et al., 2006b).
Finally, using ICR mice as a model for evaluating itch
mediators and mechanisms (Inagaki et al., 2001), topical
application of STZ in conjunction with compound 48/80,
resulted in the abrogation of scratching behavior (Figure 5a).
As COX enzymes have a crucial role in the biosynthesis of
prostanoids, we used ibuprofen, a nonselective COX
inhibitor, or the selective DP1 receptor antagonist,
MK0524, to further delineate the signaling pathway. Topical
application of ibuprofen and MK0524 for 30minutes,
followed by STZ or compound 48/80 treatments led to a
reversal of the inhibition caused by STZ. It is also worth
discussing that blocking the DP1 receptor by using MK0524
along with compound 48/80 augmented the scratching
behavior in mice (Figure 5b) and this observation corrobo-
rates our in vitro mast cell degranulation results with the
receptor antagonist. Activation of mast cells by compound
48/80 leads to the release of low levels of PGD2 in addition to
several itch mediators. PGD2 acts as a natural anti-itch agent
by suppressing mast cell degranulation, which is confirmed
by our in vitro and in vivo data. The exact potential of
compound 48/80 to elicit an itch response is evident by our
in vivo results with the DP1 receptor antagonist. STZ
enhances PGD2 production and mitigates the pruritic effects
of compound 48/80 through this mode of action. The in vivo
results also suggest that topically applied STZ may affect mast
cells, and possibly macrophages. Overall, our data reveal one
of the plausible mechanisms through which this antimycotic
agent might exert its anti-itch effects. There can also be other
modes of action by which STZ affects pruritus. For instance, it
has also been shown that Substance P evokes a scratching
response in mast cell-deficient mice as well (Andoh et al.,
1998). Such an effect might be mediated by pathways
different from those discussed in this study.
Fungal infections represent the second most frequently
reported skin disease in the United States after acne
(Weinstein and Berman, 2002), and the broad-spectrum
antimycotic efficacy of STZ (Ertaczo, 2%) is well established
(Weinstein and Berman, 2002; Pfaller and Sutton, 2006;
Ribotsky, 2009). One of the most common dermatophyte
infections tinea pedis (specific to feet) is characterized by
irritation, burning, and itching related to severity of the
disease (Weinstein and Berman, 2002). On the basis of our
observations, topical induction of PGD2 can potentially
mitigate the itch response associated with several dermato-
logical conditions. Collectively, our findings provide strong
evidence that PGD2 has a physiological role in the supp-
ression of pruritus by acting through the DP1 receptor, and
that the anti-itch effects of STZ are mediated by enhancing
the release of this prostanoid through activation of the p38-
MAPK pathway in mast cells and macrophages in the skin.
MATERIALS AND METHODS
Materials
STZ was obtained from Ferrer Pharmaceuticals (Barcelona, Spain).
Compound 48/80, LPS, SB203580, and NAG (b-Nitrophenyl
N-acetyl b-D-glucosaminide) were procured from Sigma (St Louis,
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MO). Phospho-p38 and p38 MAPK and a/b-tubulin antibodies were
purchased from Cell Signaling Technology (Danvers, MA). Lipofecta-
mine 2000 transfection reagent was obtained from Invitrogen Corpora-
tion (Carlsbad, CA). PGD2 and MK0524 (DP1 receptor antagonist) were
procured from Cayman Chemical Company (Ann Arbor, MI).
Cell culture
RBL-2H3 mast cells and RAW-264.7 macrophages were purchased
from ATCC (Manassas, VA) and cultured under the conditions
specified by the company. In brief, RBL-2H3 cells were maintained
in Eagle’s MEM (ATCC) containing 15% heat-inactivated fetal bovine
serum and 1% penicillin and streptomycin at 37 1C in 5% CO2. For
all degranulation studies, mast cells were grown in the above-
described media and treated in serum-free RPMI media (Invitrogen
Corporation) without phenol-red and antibiotics. RAW-264.7 cells
were maintained in DMEM (Invitrogen Corporation) containing 10%
fetal bovine serum and 1% penicillin and streptomycin at 37 1C in
5% CO2. Treatments were carried out in DMEM with 2% fetal
bovine serum and 1% penicillin and streptomycin.
Mast cell degranulation assay
RBL-2H3 mast cells grown in 48-well plates were treated with
compound 48/80 (final concentration 30 mgml1) alone or after
pretreatment with the indicated doses of STZ in the absence or
presence of the p38 MAPK inhibitor, SB203580 (10 mM) for 15 or
30minutes in phenol red-free and serum-free RPMI media. After
incubation, the tissue culture (media) supernatants were collected
and cellular pellets were lysed using 0.1% Triton X-100 in PIPES
buffer. A small volume of the supernatants and pellets were collected
and mixed with an equal volume of NAG dissolved in 0.1 M citrate
buffer for 60–90minutes. The reaction was stopped by the addition
of 0.1M sodium carbonate-bicarbonate buffer, and the plate was read
at 405nm. Degranulation was assessed by measuring levels of the
granule marker: % b-hexosaminidase release was calculated as the
optical density of supernatant at 405nm 100/(optical density of
supernatantþ optical density of pellet).
Measurement of PGD2 release
Detection of PGD2 in the supernatants of macrophages and mast
cells was performed using a PGD2 competitive ELISA kit (Cayman
Chemical Company), according to manufacturer’s protocol.
Western blotting
RBL-2H3 cells grown in 6-well plates were treated with STZ at a final
concentration of 1mgml1 for the indicated time periods. Cells were
then washed with cold phosphate-buffered saline and lysed with
RIPA lysis buffer. Lysates were centrifuged and total protein was
estimated in the supernatants using a bicinchoninic acid protein
assay kit (Pierce–Thermo Fisher Scientific, Rockford, IL). Protein
(25 mg) was loaded on SDS-PAGE, followed by immunoblotting with
specific antibodies (incubation with primary antibodies diluted
1:1,000 overnight at 4 1C) and detection using the ECL chemilumi-
nescence detection system (Amersham Life Sciences–GE Healthcare,
Piscataway, NJ).
In vivo scratching model
All procedures used in these experiments were approved by the
Institutional Animal Care and Use Committee at Johnson and Johnson.
An itch-associated response was induced by intradermal injec-
tion of compound 48/80 in ICR mice (Sur et al., 2008b) Mice were
individually housed in a plastic cage for at least 1 hour before the
experiment for acclimation, then pretreated for 30minutes with
topical application of vehicle control, or 10mgml1 (1%) STZ
prepared in 100% ethanol (50 ml final volume), to an area of the back
that had been shaved 1 day before the experiment. Each group
consisted of 8–14 mice. Compound 48/80 was prepared in sterile
physiological saline, then 50ml of a 1 mg ml1 solution was injected
into the interscapular part of the back, the number of scratches
elicited during the 30-minute period after injection was determined
as described previously (Liebel et al., 2006), and the number of
scratches counted by visual observation conducted independently
by two individuals. Ibuprofen (1% solution in ethanol) or the PGD2
receptor antagonist, MK0524 (0.1% in ethanol) were also used for
30minutes pretreatment (50ml volume topically applied), followed
by STZ and/or compound 48/80 treatments.
Statistical analysis
Data are presented as mean±SD. A one-way analysis of variance
with Newman–Keuls post hoc test was used to determine signifi-
cance. A value of Po0.05 was considered significant.
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